SEARCH

SEARCH BY CITATION

References

  • 1
    Broer S, Broer A, Hamprecht B. The 4F2hc surface antigen is necessary for expression of system 1-like neutral amino acid-transport activity in C6-BU-1 rat glioma cells: evidence from expression studies in Xenopus laevis oocytes. Biochem J 1995; 312: 86370.
  • 2
    Haynes BF, Hemler ME, Mann DL et al . Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol 1981; 126: 140914.
  • 3
    Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 23 62932.
  • 4
    Masuko T, Abe J, Yagita H, Hashimoto Y. Human bladder cancer cell-surface antigens recognized by murine monoclonal antibodies raised against T24 bladder cancer cells. Jpn J Cancer Res 1985; 76: 38694.
  • 5
    Yagita H, Masuko T, Hashimoto Y. Inhibition of tumor cell growth in vitro by murine monoclonal antibodies that recognize a proliferation-associated cell surface antigen system in rats and humans. Cancer Res 1986; 46: 147884.
  • 6
    Yagita H, Masuko T, Takahashi N, Hashimoto Y. Monoclonal antibodies that inhibit activation and proliferation of lymphocytes. I. Expression of the antigen on monocytes and activated lymphocytes. J Immunol 1986; 136: 205561.
  • 7
    Hara K, Kudoh H, Enomoto T, Hashimoto Y, Masuko T. Malignant transformation of NIH3T3 cells by overexpression of early lymphocyte activation antigen CD98. Biochem Biophys Res Commun 1999; 262: 7205.
  • 8
    Hara K, Kudoh H, Enomoto T, Hashimoto Y, Masuko T. Enhanced tumorigenicity caused by truncation of the extracellular domain of GP125/CD98 heavy chain. Oncogene 2000; 19: 620915.
  • 9
    Shishido T, Uno S, Kamohara M et al . Transformation of BALB3T3 cells caused by over-expression of rat CD98 heavy chain (HC) requires its association with light chain: mis-sense mutation in a cysteine residue of CD98HC eliminates its transforming activity. Int J Cancer 2000; 87: 31116.
  • 10
    Mastroberardino L, Spindler B, Pfeiffer R et al . Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 1998; 395: 28891.
  • 11
    Ohgimoto S, Tabata N, Suga S et al . Molecular characterization of fusion regulatory protein-1 (FRP-1) that induces multinucleated giant cell formation of monocytes and HIV gp160-mediated cell fusion. FRP-1 and 4F2/CD98 are identical molecules. J Immunol 1995; 155: 358592.
  • 12
    Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 1997; 390: 815.
  • 13
    Warren AP, Patel K, McConkey DJ, Palacios R. CD98: a type II transmembrane glycoprotein expressed from the beginning of primitive and definitive hematopoiesis may play a critical role in the development of hematopoietic cells. Blood 1996; 87: 367687.
  • 14
    Nakamura E, Sato M, Yang H et al . 4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer. J Biol Chem 1999; 274: 300916.
  • 15
    Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai Y. Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem 1999; 274: 19 74551.
  • 16
    Pineda M, Fernandez E, Torrents D et al . Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an l-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem 1999; 274: 19 73844.
  • 17
    Rossier G, Meier C, Bauch C et al . LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem 1999; 274: 34 94854.
  • 18
    Torrents D, Estevez R, Pineda M et al . Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y+L: A candidate gene for lysinuric protein intolerance. J Biol Chem 1998; 273: 32 43745.
  • 19
    Pfeiffer R, Rossier G, Spindler B, Meier C, Kuhn L, Verrey F. Amino acid transport of y+L-type by heterodimers of 4F2hc/CD98 and members of the glycoprotein-associated amino acid transporter family. EMBO J 1999; 18: 4957.
  • 20
    Fukasawa Y, Segawa H, Kim JY et al . Identification and characterization of a Na+-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral d- and l-amino acids. J Biol Chem 2000; 275: 96908.
  • 21
    Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 1999; 274: 11 4558.
  • 22
    Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990; 70: 4377.
  • 23
    Grudzinski W, Matula M, Sielewiesiuk J, Kernen P, Krupa Z, Gruszecki WI. Effect of 13-cis violaxanthin on organization of light harvesting complex II in monomolecular layers. Biochim Biophys Acta 2001; 1503: 291302.
  • 24
    Sang J, Lim YP, Panzica M, Finch P, Thompson NL. TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation. Cancer Res 1995; 55: 11529.
  • 25
    Wolf DA, Wang S, Panzica MA, Bassily NH, Thompson NL. Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products. Cancer Res 1996; 56: 501222.
  • 26
    Yanagida O, Kanai Y, Chairoungdua A et al . Human l-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001; 1514: 291302.
  • 27
    Gibbs RA, Weinstock GM, Metzker ML et al . Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 2004; 428: 493521.
  • 28
    Yoon JH, Kim IJ, Kim H et al . Amino acid transport system L is differently expressed in human normal oral keratinocytes and human oral cancer cells. Cancer Lett 2005; 222: 23745.
  • 29
    Burstein HJ, Kuter I, Campos SM et al . Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 272230.
  • 30
    Carter P, Presta L, Gorman CM et al . Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 42859.
  • 31
    Cobleigh MA, Vogel CL, Tripathy D et al . Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 263948.
  • 32
    Slamon DJ, Leyland-Jones B, Shak S et al . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 78392.
  • 33
    Tokuda Y, Watanabe T, Omuro Y et al . Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 1999; 81: 141925.
  • 34
    Vogel CL, Cobleigh MA, Tripathy D et al . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 71926.
  • 35
    Tokuda Y, Ohnishi Y, Shimamura K et al . In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 1996; 73: 13625.
  • 36
    Tokuda Y, Okumura A, Ohta M et al . A humanized anti-c-erbB-2 monoclonal antibody for the treatment of breast cancer. Breast Cancer 1997; 4: 26972.
  • 37
    Cunningham D, Humblet Y, Siena S et al . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 33745.
  • 38
    Chung KY, Shia J, Kemeny NE et al . Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 180310.
  • 39
    Reff ME, Carner K, Chambers KS et al . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 43545.
  • 40
    Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 471116.
  • 41
    Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al . IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 326674.
  • 42
    Maloney DG, Liles TM, Czerwinski DK et al . Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 245766.
  • 43
    McLaughlin P, Grillo-Lopez AJ, Link BK et al . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 282533.
  • 44
    Tobinai K, Kobayashi Y, Narabayashi M et al . Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998; 9: 52734.
  • 45
    Wilson WH. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin Oncol 2000; 27: 306.